Devicare to raise $3 million from Advanced MedTech

Devicare, a Barcelona, Spain-based company developing digital therapeutic solutions (DTx) to improve in-home management of chronic diseases, announced closing a $3 million Series A funding.

The money was raised from investors led by Advanced MedTech from Singapore. Existing investors Emesa Capital and Juan Knuth participated in the funding round together with Ship2B through Equity4Good, its impact investment vehicle.

Proceeds will be used to further develop Devicare’s Lit-Control medical device for kidney stone patients and comprises of a pH meter connected via Bluetooth to a mobile app. The pH meter is uniquely designed to deliver personalized medicine by digitally measuring patients’ urine pH and recommending the correct medication, then transmitting the information to an app that will adjust the dosage and allows doctors and patients to manage the condition remotely. 

Devicare, founded in 2012 and led by CEO Rosendo Garganta, is a specialty biotech company dedicated to developing pathbreaking medical treatments in Urology combining the most recent scientific advances in nutritional therapy with digital technologies.

Devicare previously raised EUR 3 million via Capital Cell in 2019.